Restasis Buyers Hit Allergan With Antitrust Suit
A proposed class of Restasis buyers on Friday accused Allergan Inc. in Texas federal court of blocking low-cost generics for the dry-eye medication through improperly obtained patents, sham infringement suits and...To view the full article, register now.
Already a subscriber? Click here to view full article